UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report Pursuant to Section 13
or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 23, 2009
Metabasis Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-50785 |
|
33-0753322 |
|
(State or other
jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
|
|
|
|
|
|
11119
North Torrey Pines Road |
|
92037 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code: (858) 587-2770
Not
Applicable.
(Former name or
former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On March 23, 2009, we announced the results of our recently completed 14-day clinical trial in which MB07803, our product candidate for the treatment of type 2 diabetes, was administered twice-daily to patients with poorly controlled type 2 diabetes. The announcement was made in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release of Metabasis Therapeutics, Inc. dated March 23, 2009. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
METABASIS THERAPEUTICS, INC. |
|
|
|
|
|
|
|
By: |
/s/ Tran B. Nguyen, MBA |
|
|
|
Tran B. Nguyen, MBA |
|
|
|
Vice President, Chief Financial Officer and |
|
|
|
Secretary |
|
|
|
|
|
Date: March 23, 2009 |
|
|
3
INDEX TO EXHIBITS
|
Number |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release of Metabasis Therapeutics, Inc. dated March 23, 2009. |
4